Histogenics (NASDAQ:HSGX) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.05), MarketWatch Earnings reports.
Histogenics stock traded down $0.03 during midday trading on Friday, reaching $0.51. 1,795,036 shares of the company traded hands, compared to its average volume of 8,070,151. The company has a market cap of $15.64 million, a price-to-earnings ratio of -0.52 and a beta of 1.02. Histogenics has a 12 month low of $0.50 and a 12 month high of $3.35.
HSGX has been the topic of a number of research analyst reports. Brookline Cap M restated a “buy” rating on shares of Histogenics in a research report on Wednesday, August 1st. HC Wainwright restated a “buy” rating and set a $3.50 price objective on shares of Histogenics in a research report on Monday, August 13th. Zacks Investment Research downgraded shares of Histogenics from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. BTIG Research downgraded shares of Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 price objective on the stock. in a research report on Wednesday, September 5th. Finally, Needham & Company LLC increased their price objective on shares of Histogenics to $5.00 and gave the company a “buy” rating in a research report on Thursday, September 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $3.25.
WARNING: This piece of content was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.baseballdailydigest.com/2018/11/10/histogenics-hsgx-issues-earnings-results-misses-estimates-by-0-05-eps.html.
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.